Viveve Medical (VIVE) 10-K 24 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 15, 2016	Jun. 30, 2015
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	879,682
Trading Symbol	vivmf
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		59,929,535
Entity Public Float			$ 21,592,523
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 7,360,000	$ 895,000
Accounts receivable	593,000	6,000
Inventory	1,549,000	131,000
Prepaid expenses and other current assets	1,615,000	923,000
Total current assets	11,117,000	1,955,000
Property and equipment, net	239,000	187,000
Other assets	138,000	156,000
Total assets	11,494,000	2,298,000
Current liabilities:
Accounts payable	1,432,000	416,000
Accrued liabilities	1,293,000	223,000
Notes Payable, Current	4,833,000	2,500,000
Total liabilities	$ 7,558,000	$ 3,139,000
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Preferred stock, no par value; unlimited shares authorized; no shares issued and outstanding as of December 31, 2015 and 2014
Common stock and paid-in capital, no par value; unlimited shares authorized as of December 31, 2015 and 2014; 59,919,025 and 18,341,294 shares issued and outstanding as of December 31, 2015 and 2014, respectively	$ 52,447,000	$ 35,244,000
Accumulated deficit	(48,511,000)	(36,085,000)
Total stockholders’ equity (deficit)	3,936,000	(841,000)
Total liabilities and stockholders’ equity (deficit)	$ 11,494,000	$ 2,298,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Preferred Stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	59,919,025	18,341,294
Common stock, shares outstanding (in shares)	59,919,025	18,341,294

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue	$ 1,447	$ 90
Cost of revenue	985	50
Gross profit	462	40
Operating expenses:
Research and development	4,988	1,426
Selling, general and administrative	7,464	4,276
Total operating expenses	12,452	5,702
Loss from operations	(11,990)	(5,662)
Interest expense	(415)	(567)
Other income (expense), net	(21)	49
Comprehensive and net loss	$ (12,426)	$ (6,180)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.31)	$ (1.27)
Weighted average shares used in computing net loss per common share
Basic and diluted (in shares)	40,181,427	4,865,546

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Extinguishment of Related Party Debt [Member]Common Stock Including Additional Paid in Capital [Member]	Rights to Shares [Member]Common Stock Including Additional Paid in Capital [Member]	May 2015 Private Placement Offering [Member]Common Stock Including Additional Paid in Capital [Member]	May 2015 Private Placement Offering [Member]	November 2015 Private Placement Offering [Member]Common Stock Including Additional Paid in Capital [Member]	November 2015 Private Placement Offering [Member]	Series A Preferred Stock [Member]Preferred Stock [Member]	Series B Preferred Stock [Member]Preferred Stock [Member]	Common Stock [Member]	Common Stock Including Additional Paid in Capital [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance, shares outstanding (in shares) at Dec. 31, 2013							23,863,302	171,199,348	6,555,305
Balance at Dec. 31, 2013							$ 24	$ 171	$ 7		$ 22,396	$ (29,905)	$ (7,307)
Extinguishment of convertible notes debt and related related accrued interest pursuant to Merger Agreement											5,397		5,397
Extinguishment of warrants											572		572
Stock exchange pursuant to Merger Agreement (in shares)							(23,863,302)	(171,199,348)	(6,555,305)	3,743,282
Stock exchange pursuant to Merger Agreement							$ (24)	$ (171)	$ (7)	$ 28,551	$ (28,365)		(16)
Issuance of common stock upon automatic conversion of warrant in connection with extinguishment of related party convertible notes (in shares)	943,596	1,179,461
PLC common stock assumed in connection with Merger (in shares)										2,024,217
Private placement offering, net of issuance costs (in shares)										8,389,187
Private placement offering, net of issuance costs										$ 4,204			4,204
Conversion of outstanding amount of principal and interest of certain bridge notes in connection with private placement offering (in shares)										2,916,380
Conversion of outstanding amount of principal and interest of certain bridge notes in connection with private placement offering										$ 1,546			1,546
Issuance of warrant in connection with note payable										622			622
Fair value of warrants issued to service providers										137			137
Stock-based compensation expense										$ 184			$ 184
Exercise of stock option (in shares)										160			160
Cancellation of shares in exchange for rights to shares (in shares)										(854,989)
Net loss												(6,180)	$ (6,180)
Balance, shares outstanding (in shares) at Dec. 31, 2014										18,341,294
Balance at Dec. 31, 2014										$ 35,244		(36,085)	(841)
Issuance of common stock upon automatic conversion of warrant in connection with extinguishment of related party convertible notes (in shares)		566,038
Private placement offering, net of issuance costs (in shares)			32,432,432		8,573,385
Issuance of warrant in connection with note payable										10			10
Fair value of warrants issued to service providers										251			251
Stock-based compensation expense										$ 220			220
Net loss												(12,426)	(12,426)
Balance, shares outstanding (in shares) at Dec. 31, 2015										59,919,025
Balance at Dec. 31, 2015										$ 52,447		$ (48,511)	3,936
May 2015 Offering, net of issuance costs			$ 11,040	$ 11,040	$ 5,393	$ 5,393
Issuance of warrants to employees for performance bonuses										$ 286			286
Exercise of warrant (in shares)										5,876
Exercise of warrant										$ 3			$ 3

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (12,426,000)	$ (6,180,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	77,000	56,000
Stock-based compensation	220,000	184,000
Fair value of warrants issued to employees for bonuses	286,000
Fair value of warrants issued to service providers	251,000	137,000
Revaluation of fair value of warrant liability		(52,000)
Non-cash interest expense	197,000	418,000
Loss on disposal of property and equipment		2,000
Changes in assets and liabilities:
Accounts receivable	(587,000)	(6,000)
Inventory	(1,438,000)	97,000
Prepaid expenses and other current assets	(879,000)	(41,000)
Other noncurrent assets	18,000	(112,000)
Accounts payable	1,016,000	(551,000)
Accrued liabilities	1,070,000	57,000
Net cash used in operating activities	(12,195,000)	(5,991,000)
Cash flows from investing activities:
Purchase of property and equipment	(109,000)	(117,000)
Net cash used in investing activities	(109,000)	(117,000)
Cash flows from financing activities:
Net cash proceeds from issuance of common stock in connection with private placement offerings	16,433,000	4,204,000
Proceeds from note payable	2,500,000	2,500,000
Repayments of notes payable	(167,000)	(1,631,000)
Proceeds from exercise of warrant	3,000
Proceeds from related party convertible bridge notes		1,500,000
Net cash provided by financing activities	18,769,000	6,573,000
Net increase in cash and cash equivalents	6,465,000	465,000
Cash and cash equivalents - beginning of period	895,000	430,000
Cash and cash equivalents - end of period	7,360,000	895,000
Supplemental disclosure:
Cash paid for interest	196,000	149,000
Cash paid for income taxes	1,000	1,000
Supplemental disclosure of cash flow information as of end of period:
Net transfer of equipment between inventory and property and equipment	20,000
Issuance of warrant in connection with note payable	$ 10,000	622,000
Conversion of certain bridge notes and related accrued interest in connection with private placement offering		1,546,000
Extinguishment of convertible notes debt and related related accrued interest pursuant to Merger Agreement		5,397,000
Extinguishment of warrants pursuant to Merger Agreement		572,000
Payable to non-accredited investors in connection with Merger Agreement		$ 16,000

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation On September 23, 2014, Viveve® Medical, Inc. (formerly PLC Systems Inc.) a Yukon Territory corporation (“ Viveve Medical”, the “Company”, “we”, “our”, or “us”) completed a reverse acquisition and recapitalization pursuant to the terms and conditions of an Agreement and Plan of Merger (“Merger Agreement”) by and among the Company, Viveve, Inc., a Delaware corporation (“Viveve”) and PLC Systems Acquisition Corp., a wholly owned subsidiary of the Company (the “Merger”). As of that date, Viveve operates as a wholly-owned subsidiary of the Company and on that date the Company changed its name from PLC Systems Inc. to Viveve Medical, Inc. Viveve Medical competes in the women’s health industry by marketing the Viveve System™ as a way to improve the overall sexual well-being and quality of life of women suffering from vaginal laxity. Viveve Medical retained all its personnel following the Merger and continues to be headquartered in Sunnyvale, California. At the effective time of the Merger, the Company divested the ownership of its former operating subsidiaries, PLC Medical Systems, Inc. and PLC Systemas Medicos Internacionais, which, following the Merger, operate as independent entities under new ownership. In connection with the Merger, certain outstanding convertible bridge notes in the aggregate principal amount of $4,875,000 and related accrued interest of approximately $522,000 were extinguished. Additionally, warrant liabilities of Viveve for approximately $572,000 were extinguished in connection with the Merger. Pursuant to the Merger Agreement, all shares of capital stock (including common and preferred stock) of Viveve owned by accredited investors were converted into 3,743,282 shares of the Company's common stock which represented approximately 62% of the issued and outstanding shares of common stock of the Company on a fully diluted basis. In addition, non-accredited investors of Viveve were entitled to receive, on a pro-rata basis, an aggregate of approximately $16,000 in exchange for the shares of common stock of Viveve owned by such shareholders upon closing. Upon the closing of the Merger, an additional 943,596 shares of the Company’s common stock were issued upon the automatic conversion of a warrant issued in exchange for the cancellation of related party convertible bridge notes. The acquisition was accounted for as a reverse merger and recapitalization effected by a share exchange. Viveve was considered the acquirer for accounting and financial reporting purposes. The assets and liabilities of the acquired entity were brought forward at their book value and no goodwill was recognized. Concurrent with the Merger, Viveve Medical completed a private placement for total gross proceeds of approximately $6 million (including the conversion of approximately $1.5 million in outstanding convertible bridge notes) (the “September 2014 Offering”). As a result, Viveve Medical issued 11,305,567 shares of common stock (which excludes an additional 101,365 shares of common stock which were not issued as a result of beneficial ownership limitations) and 5-year warrants to purchase up to 940,189 shares of common stock at an exercise price of $0.53 per share. On May 14, 2015, in connection with the closing of a private placement (the “May 2015 Offering”), Viveve Medical issued an aggregate of 32,432,432 shares of common stock at $0.37 per share for gross proceeds of approximately $12,000,000 in accordance with the terms and conditions of those certain Securities Purchase Agreements by and between the Company and certain accredited investors. The net proceeds to the Company after the deduction of placement agent commissions and other expenses were approximately $11,040,000. On November 24, 2015, in connection with the closing of a private placement (the “November 2015 Offering”), Viveve Medical issued an aggregate of 8,573,385 shares of common stock at $0.70 per share for gross proceeds of approximately $6,000,000 in accordance with the terms and conditions of those certain Securities Purchase Agreements by and between the Company and certain accredited investors. The net proceeds to the Company after the deduction of placement agent commissions and other expenses were approximately $5,393,000. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses from operations since its inception and has an accumulated deficit of $48,511,000 as of December 31, 2015. Management expects operating losses to continue through the foreseeable future. The Company's ability to transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The Company has not generated significant revenues and has funded its operating losses through the sale of preferred and common stock and the issuance of debt. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the industry. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability. Management of the Company intends to raise additional funds through the issuance of equity securities. There can be no assurance that such financing will be available or on terms which are favorable to the Company. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not contain any adjustments that might result from the outcome of this uncertainty.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve and Viveve BV (which was established in January 2015). All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less, at the time of purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand accounts primarily at one financial institution. Deposits in this institution may, from time to time, exceed the federally insured amounts. Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows. The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the Viveve System are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third-party suppliers would adversely impact the production of our products for a substantial period of time, which could have a material adverse effect on our business, financial condition, operating results and cash flows. During the year ended December 31, 2015, four customers accounted for 87% of the Company’s revenue. During the year ended December 31, 2014, two customers accounted for 91% of the Company’s revenue. As of December 31, 2015, three customers accounted for 86% of total accounts receivable. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectibility of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2015 and 2014, there was no allowance for doubtful accounts. Inventory Inventory is stated at the lower of cost or market. Cost is determined on an actual cost basis on a first-in, first-out method. Lower of cost or market is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new lower-cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five years. The amortization of the demos is charged to selling, general and administrative expense and the demos are included in the medical equipment line within the property and equipment, net balance on the consolidated balance sheets as of December 31, 2015 and 2014. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three to seven years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful lives or the life of the lease. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date. Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong, Japan, Europe, the Middle East and Southeast Asia. The Company does not provide its customers with a contractual right of return. Product Warranty The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework or replacement of products (at the Company’s option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward. Shipping and Handling Costs The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue. Advertising Costs Advertising costs are charged to general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2015 and 2014. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities. Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not likely, the Company establishes a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against the net deferred tax assets. The Company recorded a full valuation allowance as of December 31, 2015 and 2014. Based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize its deferred tax assets in the future. The Company intends to maintain valuation allowances until sufficient evidence exists to support the reversal of such valuation allowances. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans. Should the actual amounts differ from the Company’s estimates, the carrying value of the Company’s deferred tax assets could be materially impacted. The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not believe there are any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2015 and 2014, the Company’s comprehensive loss is the same as its net loss. Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, warrants to purchase common stock, stock options and rights to common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2015 2014 Stock options to purchase common stock 8,177,291 2,291,783 Warrants to purchase common stock 3,066,447 1,793,887 Rights to common stock - 566,038 Recently Issued and Adopted Accounting Standards In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements. In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved After a Requisite Service Period” (“ASU 2014-12”). Companies commonly issue share-based payment awards that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The performance target should not be reflected in estimating the grant date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. ASU 2014-12 will be effective for the Company’s fiscal year beginning fiscal 2016 and interim reporting periods within that year, using either the retrospective or prospective transition method. Early adoption is permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company’s fiscal year beginning January 1, 2016 and subsequent interim periods, with earlier adoption permitted. We will adopt this guidance in the first quarter of 2016. We do not expect the adoption of this guidance to have a material effect on our consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”). ASU 2015-11 requires that an entity should measure inventory within the scope of this pronouncement at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The pronouncement does not apply to inventory that is being measured using the last-in, first-out (“LIFO”) or the retail inventory method. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. ASU 2015-11 will be effective for the Company’s fiscal year beginning January 1, 2017 and subsequent interim periods, with earlier adoption permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” ("ASU 2015-17'), which amends existing guidance to require that deferred income tax liabilities and assets be classified as noncurrent in a classified balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified balance sheet. The standard is effective for the Company’s fiscal year 2017. Early adoption is permitted. As permitted by ASU 2015-17, the Company early-adopted this standard and applied it retrospectively to all periods of the tax provision presented. As the Company has a full valuation allowance against the deferred assets, there is no impact to the consolidated financial statements. The Company has reflected the change of this pronouncement in Note 12 to the consolidated financial statements.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value. Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 investments generally does not require significant judgment, and the estimation is not difficult. Level 2 Pricing is provided by third party sources of market information obtained through investment advisors. The Company does not adjust for or apply any additional assumptions or estimates to the pricing information received from its advisors. Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The determination of fair value for Level 3 instruments involves the most management judgment and subjectivity. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no financial instruments that were measured at fair value on a recurring basis as of December 31, 2015 and 2014. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2015 and 2014 approximate fair value because of the short maturity of these instruments. Based on borrowing rates currently available to the Company for loans with similar terms, the carrying value of the notes payable approximates fair value. There were no changes in valuation technique from prior periods.

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2015 and 2014 (in thousands): Life December 31, (in years) 2015 2014 Medical equipment 5 $ 454 $ 367 Computer equipment 3 56 39 Furniture and fixtures 7 24 13 534 419 Less: Accumulated depreciation and amortization (295 ) (232 ) Property and equipment, net $ 239 $ 187 Depreciation and amortization expense for the years ended December 31, 2015 and 2014 was $77,000 and $56,000, respectively.

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2015 and 2014 (in thousands): December 31, 2015 December 31, 2014 Accrued professional fees $ 388 $ 117 Accrued clinical trial costs 112 - Accrued bonuses 613 - Accrued vacation 68 86 Other accruals 112 20 Total accrued liabilities $ 1,293 $ 223

Note 6 - Note Payable

Note 6 - Note Payable	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On September 30, 2014, we entered into a Loan and Security Agreement, as amended on February 19, 2015 and May 14, 2015 (collectively, the “Loan Agreement”), pursuant to which we received a term loan in the amount of $5.0 million, funded in 3 tranches. The first tranche of $2.5 million was provided to us on October 1, 2014. The proceeds from the first tranche were used to repay the existing loan with a financial institution which totaled approximately $1,631,000 and the balance was used for general working capital purposes and capital expenditures. The first tranche borrowing is repayable in interest only payments until November 1, 2015 and then 30 equal monthly installments of principal and interest at a rate of 5.25% per annum. The second tranche of the term loan is equal to $1.5 million, of which $500,000 was provided to us on each of February 19, 2015, March 16, 2015 and April 6, 2015. The second tranche borrowings in February, March and April 2015 are repayable in interest only payments until March 1, 2016 and then 30 equal monthly installments of principal and interest at a rate of 5.00%, 5.06% and 5.00% per annum, respectively. The Company provided evidence to the lender of positive three month interim results with respect to the Company’s randomized, blinded and sham-controlled clinical trial in Europe and Canada (the “OUS Clinical Trial”), and on July 15, 2015 we received the final $1,000,000 drawdown of funds from the third tranche. The third tranche borrowing is repayable in interest only payments until August 1, 2016 and then 30 equal monthly installments of principal and interest at a rate of 6.56% per annum. The proceeds from the second and third tranches will be used for general working capital purposes and capital expenditures. As of December 31, 2015 and 2014, the note payable had an outstanding term loan principal balance of $4.8 million and $2.5 million, respectively, which is recorded as a current liability on the consolidated balance sheets. All borrowings under the Loan Agreement are collateralized by substantially all of the Company’s assets, including intellectual property. The Loan Agreement also requires that the Company comply with certain financial covenants and milestones in connection with the OUS Clinical Trial, including, but not limited to, (a) full enrollment as of March 31, 2015, (b) positive 3-month interim data as of July 10, 2015, and (c) positive results from the trial as of January 31, 2016. Full enrollment of the OUS Clinical Trial was achieved prior to March 31, 2015 and the Company provided evidence to the lender of positive 3-month interim results with respect to the Company’s OUS Clinical Trial prior to July 10, 2015. As of December 31, 2015, the Company was in compliance with all covenants of the Loan Agreement. In connection with the Loan Agreement, the Company issued a 10-year warrant to the lender for the purchase of 471,698 shares of the Company’s common stock at $0.53 per share. In connection with the first loan amendment in February 2015, the Company also amended the terms of the warrant issued to the lender to provide for an automatic increase of the number of shares the lender may acquire in the event the Company fails to meet certain covenants. In connection with the second loan amendment in May 2015, the Company issued a second 10-year warrant to the lender to purchase a total of 25,000 shares of common stock at an exercise price of $0.37 per share. (See Note 8.) The Loan Agreement with the financial institution contains a material adverse change clause, as defined in the Loan Agreement, which would result in an event of default if the lender deems a material adverse change to have occurred to the Company’s business. The continuing liquidity issues the Company faces could be construed by the lender (or any subsequent note holder) as a material adverse change which could trigger an acceleration of all of the outstanding debt. As such, the Company has classified all of its outstanding debt balance as a current liability as of December 31, 2015 and 2014. As of December 31, 2015, future minimum payments under the note payable are as follows (in thousands): Year Ending December 31, 2016 $ 1,894 2017 2,124 2018 1,161 2019 34 Total payments 5,213 Less: Amount representing interest (380 ) Present value of obligations 4,833 Less: Notes payable, current portion 4,833 Note payable, noncurrent portion $ -

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Operating Lease In January 2012, the Company entered into a lease agreement for office and laboratory facilities. The lease agreement, as amended in January 2015, commenced in March 2012 and will terminate in March 2017. Rent expense for the years ended December 31, 2015 and 2014 was $210,000 and $171,000, respectively. As of December 31, 2015, future minimum payments under the lease are as follows (in thousands): Year Ending December 31, 2016 229 2017 58 Total minimum lease payments $ 287 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not breached the agreement and/or the loss is not attributable to the indemnified party’s negligence or willful malfeasance. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these agreements is minimal. Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceedings in considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may revise its estimates, which could materially impact the consolidated financial statements.

Note 8 - Common Stock

Note 8 - Common Stock	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Common Stock In conjunction with the September 2014 Offering, the Company entered into a Right to Shares Agreement with certain investors. Pursuant to this agreement, 854,989 shares of common stock purchased by the investors in the September 2014 Offering were cancelled. The Company is obligated to issue, and the investors have the right to receive up to 956,354 shares of the Company’s common stock, which includes 101,365 shares that were not issued in the September 2014 Offering due to beneficial ownership limitations. No additional consideration will be The Company assessed the provisions of the Buy-In Share feature of the Right to Shares Agreements as an embedded derivative and has concluded that the feature meets the definition of a derivative and is not clearly and closely related to the Rights to Shares equity host agreement. The Buy-In Shares feature has been bifurcated from the Rights to Shares agreement and accounted for separately. The value of this feature was nominal as of the issuance date and December 31, 2014. On May 14, 2015, in connection with the closing of the May 2015 Offering, we issued an aggregate of 32,432,432 shares of common stock at $0.37 per share for gross proceeds of approximately $12,000,000 in accordance with the terms and conditions of those certain Securities Purchase Agreements by and between the Company and certain accredited investors. The net proceeds to the Company after the deduction of placement agent commissions and other expenses were approximately $11,040,000. On November 24, 2015, in connection with the closing of the November 2015 Offering, we issued an aggregate of 8,573,385 shares of common stock at $0.70 per share for gross proceeds of approximately $6,000,000 in accordance with the terms and conditions of those certain Securities Purchase Agreements by and between the Company and certain accredited investors. The net proceeds to the Company after the deduction of placement agent commissions and other expenses were approximately $5,393,000. Warrants for Common Stock As of December 31, 2015, outstanding warrants to purchase an aggregate of 3,066,447 shares of common stock were as follows: Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 0.53 934,313 September 2014 Common Shares September 30, 2024 $ 0.53 471,698 October 2014 Common Shares October 13, 2019 $ 0.53 237,000 October 2014 Common Shares October 31, 2019 $ 0.53 3,750 November 2014 Common Shares November 12, 2019 $ 0.53 100,000 February 2015 Common Shares February 17, 2025 $ 0.50 605,556 March 2015 Common Shares March 26, 2025 $ 0.34 11,628 May 2015 Common Shares May 12, 2025 $ 0.53 289,827 May 2015 Common Shares May 14, 2025 $ 0.37 25,000 May 2015 Common Shares May 17, 2020 $ 0.53 172,675 December 2015 Common Shares December 16, 2025 $ 0.70 215,000 3,066,447 In connection with the September 2014 Offering, the Company issued warrants to purchase a total of 940,189 shares of common stock at an exercise price of $0.53 per share. The warrants have a contractual life of five years and are exercisable immediately in whole or in part, on or before five years from the issuance date. In connection with the Loan Agreement entered into on September 30, 2014, the Company issued a warrant to purchase a total of 471,698 shares of common stock at an exercise price of $0.53 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrant on the date of issuance to be $622,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 77%, risk free interest rate of 2.5% and a contractual life of ten years. The warrant will expire on September 30, 2024. The fair value of the warrant was recorded as debt issuance costs, included in prepaid expenses and other current assets on the consolidated balance sheets and will be amortized to interest expense over the loan term. During the years ended December 31, 2015 and 2014, the Company recorded $187,000 and $48,000, respectively, of interest expense relating to the debt issuance costs. As of December 31, 2015, the remaining unamortized debt issuance costs were $387,000. In connection with the first loan amendment in February 2015, the Company also amended the terms of the warrant issued to the lender to provide for an automatic increase of the number of shares the lender may acquire in the event the Company fails to meet certain covenants to achieve certain OUS Clinical Trial milestones or capital raising requirements as set forth in the Loan Agreement, as amended, by a number equal to the quotient derived by dividing (i) 1% of the principal balance outstanding under the Loan Agreement by (ii) the exercise price of $0.53 per share. In October and November of 2014, the Company issued common stock warrants to various vendors and nonemployee contractors to purchase a total of 382,000 shares of common stock at an exercise price of $0.53 per share. The warrants have a contractual life of five years and are exercisable in whole or in part, either immediately upon grant or in some cases upon achieving certain milestones or vesting terms. The Company determined the fair value of the warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 61.3%, risk free interest rate of 1.55% to 1.65% and a contractual life of five years. The fair values of the warrants were recorded as professional consulting fees or clinical costs, which are included in selling, general and administrative and research and development expenses in the consolidated statements of operations for the years ended December 31, 2015 and 2014, depending on the nature of the services provided. Stock-based compensation expense related to these warrants is recognized as the warrants are earned and was $40,000 and $137,000 for the years ended December 31, 2015 and 2014, respectively. A total of 41,250 shares issuable pursuant to warrants issued to two vendors in October 2014 were cancelled in 2015 as the milestones related to these shares were not achieved. In February 2015, the Company issued common stock warrants to employees for performance bonuses to purchase a total of 605,556 shares of common stock at an exercise price of $0.50 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 77.6%, risk free interest rate of 2.14% and a contractual life of ten years. The fair values of the warrants were recorded in selling, general and administrative and research and development expenses in the consolidated statements of operations, depending on the department classification of the employee. The stock-based compensation expense related to these warrants was $244,000 for the year ended December 31, 2015. In March 2015, the Company issued a common stock warrant to a nonemployee contractor to purchase a total of 11,628 shares of common stock at an exercise price of $0.34 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrant using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 78.9%, risk free interest rate of 1.94% and a contractual life of ten years. The fair value of the warrant was recorded as professional consulting fees, which are included in selling, general and administrative expenses in the consolidated statements of operations. The stock-based compensation expense related to this warrant was $3,000 for the year ended December 31, 2015. In May 2015, the Company issued common stock warrants to nonemployee contractors to purchase a total of 289,827 shares of common stock at an exercise price of $0.53 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 80.1%, risk free interest rate of 2.28% and a contractual life of ten years. The fair values of the warrants were recorded as professional consulting fees, which are included in selling, general and administrative expenses in the consolidated statements of operations. The stock-based compensation expense related to these warrants was $73,000 for the year ended December 31, 2015. In conjunction with the second loan amendment in May 2015, the Company issued a warrant to the lender to purchase a total of 25,000 shares of common stock at an exercise price of $0.37 per share. The warrant has a contractual life of ten years and is exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrant on the date of issuance to be $10,000 using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 80.1%, risk free interest rate of 2.23% and a contractual life of ten years. The fair value of the warrant was recorded as debt issuance costs, included in prepaid expenses and other current assets on the consolidated balance sheets and was amortized to interest expense over the period from the date of issuance to the end of the extended period to draw down the additional funds in connection with the third tranche or July 15, 2015. During the year ended December 31, 2015, the Company recorded $10,000 of interest expense relating to the debt issuance costs. As of December 31, 2015, the remaining unamortized debt issuance costs were zero. In May 2015, the Company issued a common stock warrant to a nonemployee contractor to purchase a total of 172,675 shares of common stock at an exercise price of $0.53 per share. The warrant has a contractual life of five years and is exercisable immediately in whole or in part, on or before five years from the issuance date. The Company determined the fair value of the warrant using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 64.4%, risk free interest rate of 1.54% and a contractual life of five years. The fair value of the warrant was recorded as professional consulting fees, which are included in selling, general and administrative expenses in the consolidated statements of operations. The stock-based compensation expense related to these warrants was $47,000 for the year ended December 31, 2015. In December 2015, the Company issued common stock warrants to employees and nonemployee contractors for performance bonuses to purchase a total of 215,000 shares of common stock at an exercise price of $0.70 per share. The warrants have a contractual life of ten years and are exercisable immediately in whole or in part, on or before ten years from the issuance date. The Company determined the fair value of the warrants using the Black-Scholes option pricing model. Assumptions used were dividend yield of 0%, volatility of 76.8%, risk free interest rate of 2.27% and a contractual life of ten years. The fair values of the warrants were recorded in selling, general and administrative and research and development expenses in the consolidated statements of operations, depending on the department classification of the employee or nonemployee contractor. The stock-based compensation expense related to these warrants was $130,000 for the year ended December 31, 2015.

Note 9 - Summary of Stock Optio

Note 9 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options from three employee benefit plans. The plans include the Company’s 2005 Stock Incentive Plan (the “2005 Plan”), the Viveve Amended and Restated 2006 Stock Plan (the “2006 Plan”) and the Company’s 2013 Stock Option and Incentive Plan (the “2013 Plan”). The 2005 Plan was adopted by the Company’s board of directors and approved by its stockholders. As of December 31, 2015, 22,095 shares of common stock remain reserved for issuance under the 2005 Plan. The Company does not intend to grant further awards from the 2005 Plan, however, it will continue to administer the 2005 Plan until all outstanding awards are exercised, expire, terminate or are forfeited. There are currently outstanding stock option awards issued from the 2005 Plan covering a total of 22,095 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $12.83 per share and the weighted average remaining contractual term is 1.36 years. The 2006 Plan was adopted by the board of directors of Viveve and was terminated in conjunction with the Merger. Prior to the Merger, the board of directors voted to accelerate the vesting of all unvested options that were outstanding as of the date of the Merger such that all options would be immediately vested and exercisable by the holders. In conjunction with the Merger, the Company agreed to assume and administer the 2006 Plan and all outstanding options to purchase shares of Viveve, Inc. common stock issued from the 2006 Plan were converted into options to purchase shares of the Company’s common stock (rounded down to the nearest whole share). The number of shares of the Company’s common stock into which the 2006 Plan options were converted was determined by multiplying the number of shares covered by each 2006 Plan option by the exchange ratio of 0.0080497. The exercise price of each 2006 Plan option was determined by dividing the exercise price of each 2006 Plan option immediately prior to the Merger by the exchange ratio of 0.0080497 (rounded up to the nearest cent). There are currently outstanding stock option awards issued from the 2006 Plan covering a total of 322,069 shares of the Company’s common stock and no shares are available for future awards. The weighted average exercise price of the outstanding stock options is $1.54 per share and the weighted average remaining contractual term is 6.64 years. The 2013 Plan was also adopted by the Company’s board of directors and approved by its stockholders. The 2013 Plan is administered by the Compensation Committee of the Company’s board of directors (the “Administrator”). Under the 2013 Plan, the Company may grant equity awards to eligible participants which may take the form of stock options (both incentive stock options and non-qualified stock options), stock appreciation rights, restricted, deferred or unrestricted stock awards, performance based awards or dividend equivalent rights. Awards may be granted to officers, employees, nonemployee directors (as defined in the 2013 Plan) and other key persons (including consultants and prospective employees). The term of any stock option award may not exceed 10 years and may be subject to vesting conditions, as determined by the Administrator. Options granted generally vest over four years. Incentive stock options may be granted only to employees of the Company or any subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Internal Revenue Code. The exercise price of any stock option award cannot be less than the fair market value of the Company’s common stock, provided, however, that an incentive stock option granted to an employee who owns more than 10% of the Company’s outstanding voting power must have an exercise price of no less than 110% of the fair market value of the Company’s common stock and a term that does not exceed five years. On July 22, 2015, the Company’s stockholders approved an amendment to the 2013 Plan increasing the number of shares of common stock authorized for awards under the 2013 Plan from 3,111,587 shares to a total of 10,100,000 shares. As of December 31, 2015, there are outstanding stock option awards issued from the 2013 Plan covering a total of 7,833,127 shares of the Company’s common stock and there remain reserved for future awards 1,944,644 shares of the Company’s common stock. The weighted average exercise price of the outstanding stock options is $0.74 per share, and the remaining contractual term is 9.51 years. Activity under the 2005 Plan, the 2006 Plan and the 2013 Plan is as follows: Year Ended December 31, 2015 Year Ended December 31, 2014 Weighted Weighted Weighted Average Aggregate Weighted Average Aggregate Number Average Remaining Intrinsic Number Average Remaining Intrinsic of Exercise Contractual Value of Exercise Contractual Value Shares Price Term (years) (in thousands) Shares Price Term (years) (in thousands) Options outstanding, beginning of period 2,291,783 $ 1.02 9.32 $ - 363,413 $ 1.24 8.80 Options granted 6,031,004 $ 0.73 1,901,476 $ 0.60 Options assumed from PLC - $ - 68,238 $ 10.24 Options exercised - $ - (160 ) $ 0.12 Options canceled (145,496 ) $ 0.69 (41,184 ) $ 1.83 Options outstanding, end of period 8,177,291 $ 0.81 9.37 $ 1,194,180 2,291,783 $ 1.02 9.32 $ - Vested and exercisable and expected to vest, end of period 7,418,006 $ 0.82 9.33 $ 1,094,069 2,099,687 $ 1.06 9.29 $ - Vested and exercisable, end of period 974,849 $ 1.58 7.20 $ 143,458 519,901 $ 2.45 7.89 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of December 31, 2015. The options outstanding and exercisable as of December 31, 2015 are as follows: Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2015 Price Term (Years) December 31, 2015 Price $0.33 100,000 $ 0.33 9.37 - $ - $0.46 - $0.47 635,000 $ 0.47 9.11 - $ - $0.60 1,768,980 $ 0.60 8.55 585,542 $ 0.60 $0.75 4,949,004 $ 0.75 9.97 - $ - $0.89 - $0.99 335,000 $ 0.96 9.60 - $ - $1.24 312,373 $ 1.24 6.79 312,373 $ 1.24 $7.00 - $9.00 57,603 $ 8.64 1.61 57,603 $ 8.64 $12.00 - $18.63 19,081 $ 15.29 1.75 19,081 $ 15.29 $37.00 250 $ 37.00 1.73 250 $ 37.00 8,177,291 $ 0.81 9.37 974,849 $ 1.58 Stock-Based Compensation During the years ended December 31, 2015 and 2014, the weighted-average grant date fair value of options granted was $0.39 and $0.32 per share, respectively. Stock-based compensation expense recognized during the year ended December 31, 2015 and 2014 was $220,000 and $184,000, respectively. As of December 31, 2015, the total unrecognized compensation cost in connection with unvested stock options was approximately $2.4 million. These costs are expected to be recognized over a period of approximately 3.71 years. The aggregate intrinsic value of options exercised during the years ended December 31, 2015 and 2014 was $0. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following assumptions: Year Ended December 31, 2015 2014 Expected term (in years) 5% 5% Average volatility 63% 61% Risk-free interest rate 1.70% 1.80% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No dividend yield is included as the Company has not issued any dividends and does not anticipate issuing any dividends in the future. The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2015 and 2014 (in thousands): Year Ended December 31, 2015 2014 Research and development $ 18 $ 5 Selling, general and administrative 202 179 Total $ 220 $ 184 Prior to the Merger, the Company’s board of directors approved the acceleration of vesting of all unvested stock options that were outstanding under the 2006 Plan as of the date of the Merger. For the year ended December 31, 2014, the Company recorded additional stock-based compensation expense (primarily in selling, general and administrative expenses in the consolidated statement of operations for the year ended December 31, 2014) of approximately $103,000 associated with the acceleration of vesting of approximately 140,000 affected stock options.

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Taxes No provision for income taxes has been recorded due to the net operating losses incurred from inception to date, for which no benefit has been recorded. A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2015 2014 Income tax provision (benefit) at statutory rate (34 )% (34 )% State income taxes, net of federal benefit (6 )% (6 )% Merger transaction costs 0 % 6 % Change in valuation allowance 39 % 37 % Other 1 % (3 )% Effective tax rate 0 % 0 % The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 10,726 $ 5,770 Capitalized start up costs 7,225 7,751 Research and development credits 248 189 Accruals and reserves 497 169 Total deferred tax assets 18,696 13,879 Deferred tax liabilities: Fixed assets and depreciation (8 ) (13 ) Valuation allowance (18,688 ) (13,866 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on it past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $4,822,000 and $2,257,000 during the years ended December 31, 2015 and 2014, respectively. As of December 31, 2015, the Company has net operating loss carryforwards for federal and state income tax purposes of approximately $26,927,000 and $26,915,000, respectively, which expire beginning in the year 2017. The Company also has federal and California research and development tax credits of approximately $214,000 and $212,000, respectively. The federal research credits will begin to expire in 2027 and the California research and development credits have no expiration date. The above net operating losses and research and development credits are subject to Sections 382 and 383 of the Internal Revenue Code. In the event of a change in ownership as defined by these code sections, the usage of the above mentioned net operating losses and research and development credits may be limited. As of December 31, 2015, the Company had not accrued any interest or penalties related to uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2015 2014 Balance at the beginning of the year $ 97 $ 83 Additions based upon tax positions related to the current year 31 14 Balance at the end of the year $ 128 $ 97 If the ending balance of $128,000 of unrecognized tax benefits as of December 31, 2015 were recognized, none of the recognition would affect the income tax rate. The Company does not anticipate any material change in its unrecognized tax benefits over the next twelve months. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	13. Related Party Transactions In June 2006, the Company entered into a Development and Manufacturing Agreement with Stellartech Research Corporation (the “Agreement”). The Agreement was amended on October 4, 2007. Under the Agreement, the Company agreed to purchase 300 generators manufactured by Stellartech. As of December 31, 2015, the Company has purchased 112 units. The price per unit is variable and dependent on the volume and timing of units ordered. In conjunction with the Agreement, Stellartech purchased 300,000 shares of Viveve’s common stock at par value (2,415 shares of the Company’s common stock post-Merger based on the exchange ratio of 0.0080497). These shares are subject to a right of repurchase by the Company, which lapses over a four-year period. As of December 31, 2015, none of the shares of common stock were subject to repurchase. Under the Agreement, the Company paid Stellartech $3,446,000 and $484,000 for goods and services during the years ended December 31, 2015 and 2014, respectively.

Note 12 - Segments and Geograph

Note 12 - Segments and Geographic Information	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Segments and Geographic Information Revenue from unaffiliated customers by geographic area were as follows (in thousands): Year Ended December 31, 2015 2014 Asia $ 889 $ 83 Europe and Middle East 551 - Rest of the world 7 7 Total $ 1,447 $ 90 The Company’s long-lived assets by geographic area were as follows (in thousands): Year Ended December 31, 2015 2014 United States $ 100 $ 60 Europe 99 106 Asia 32 - Canada 8 21 Total $ 239 $ 187 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent Events In January 2016, the Company entered into a commercial relationship with a specialized supplier of medical devices to certain Asian Pacific countries. The supplier is headquartered in Taipei, Taiwan. This exclusive, 3 year distribution relationship expands our global presence and includes minimum purchase requirements of 47 Viveve Systems in 2016, 75 in 2017 and 109 in 2018. On March 18, 2016, we entered into the Fourth Amendment to the Loan Agreement (the "Fourth Amendment") pursuant to which the lender waived certain covenant failures subsequent to December 31, 2015 including providing evidence of positive results from the OUS Clinical Trial as of January 31, 2016 and maintaining a minimum cash balance. The Fourth Amendment also extended the date for the requirement that we provide evidence of positive results from the OUS Clinical Trial and revised the minimum cash balance requirement to April 30, 2016. Following execution of the Fourth Amendment, we must maintain a balance of cash of at least $3,000,000 at the lender’s institution.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In addition, any change in these estimates or their related assumptions could have an adverse effect on our operating results.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less, at the time of purchase, to be cash equivalents. The Company’s cash and cash equivalents are deposited in demand accounts primarily at one financial institution. Deposits in this institution may, from time to time, exceed the federally insured amounts.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no assurance that any such products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed. These factors could have a material adverse effect upon the Company’s financial results, financial position, and future cash flows. The Company’s products may require approval from the U.S. Food and Drug Administration or other international regulatory agencies prior to commencing commercial sales. There can be no assurance that the Company’s products will receive any of these required approvals. If the Company was denied such approvals or such approvals were delayed, it would have a material adverse effect on the Company’s financial results, financial position and future cash flows. The Company is subject to risks common to companies in the medical device industry including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, uncertainty of market acceptance of products, product liability, and the need to obtain additional financing. The Company’s ultimate success is dependent upon its ability to raise additional capital and to successfully develop and market its products. The Company outsources the manufacture and repair of the Viveve System to a single contract manufacturer. Also, certain other components and materials that comprise the Viveve System are currently manufactured by a single supplier or a limited number of suppliers. A significant supply interruption or disruption in the operations of the contract manufacturer or these third-party suppliers would adversely impact the production of our products for a substantial period of time, which could have a material adverse effect on our business, financial condition, operating results and cash flows. During the year ended December 31, 2015, four customers accounted for 87% of the Company’s revenue. During the year ended December 31, 2014, two customers accounted for 91% of the Company’s revenue. As of December 31, 2015, three customers accounted for 86% of total accounts receivable.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectibility of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of December 31, 2015 and 2014, there was no allowance for doubtful accounts.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or market. Cost is determined on an actual cost basis on a first-in, first-out method. Lower of cost or market is evaluated by considering obsolescence, excessive levels of inventory, deterioration and other factors. Adjustments to reduce the cost of inventory to its net realizable value, if required, are made for estimated excess, obsolescence or impaired inventory. Excess and obsolete inventory is charged to cost of revenue and a new lower-cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five years. The amortization of the demos is charged to selling, general and administrative expense and the demos are included in the medical equipment line within the property and equipment, net balance on the consolidated balance sheets as of December 31, 2015 and 2014.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight line method over their estimated useful lives of three to seven years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful lives or the life of the lease. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. When such an event occurs, management determines whether there has been an impairment by comparing the anticipated undiscounted future net cash flows to the related asset’s carrying value. If an asset is considered impaired, the asset is written down to fair value, which is determined based either on discounted cash flows or appraised value, depending on the nature of the asset. The Company has not identified any such impairment losses to date.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the sale of its products, the Viveve System, single-use treatment tips and ancillary consumables. Revenue is recognized upon delivery, provided that persuasive evidence of an arrangement exists, the price is fixed or determinable and collection of the resulting receivable is reasonably assured. Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance outside the U.S. and currently sells the Viveve System in Canada, Hong Kong, Japan, Europe, the Middle East and Southeast Asia. The Company does not provide its customers with a contractual right of return.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to a one-year warranty, which provides for the repair, rework or replacement of products (at the Company’s option) that fail to perform within stated specification. The Company has assessed the historical claims and, to date, product warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs The Company includes amounts billed for shipping and handling in revenue and shipping and handling costs in cost of revenue.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs Advertising costs are charged to general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2015 and 2014.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, prototype materials, laboratory supplies, consulting costs, and allocated overhead, including rent, equipment depreciation, and utilities.
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not likely, the Company establishes a valuation allowance. Management judgment is required in determining the Company’s provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against the net deferred tax assets. The Company recorded a full valuation allowance as of December 31, 2015 and 2014. Based on the available evidence, the Company believes it is more likely than not that it will not be able to utilize its deferred tax assets in the future. The Company intends to maintain valuation allowances until sufficient evidence exists to support the reversal of such valuation allowances. The Company makes estimates and judgments about its future taxable income that are based on assumptions that are consistent with its plans. Should the actual amounts differ from the Company’s estimates, the carrying value of the Company’s deferred tax assets could be materially impacted. The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not believe there are any tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. We determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended December 31, 2015 and 2014, the Company’s comprehensive loss is the same as its net loss.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, warrants to purchase common stock, stock options and rights to common stock are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2015 2014 Stock options to purchase common stock 8,177,291 2,291,783 Warrants to purchase common stock 3,066,447 1,793,887 Rights to common stock - 566,038
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In May 2014, as part of its ongoing efforts to assist in the convergence of US GAAP and International Financial Reporting Standards (“IFRS”), the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606).” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. The ASU provides alternative methods of initial adoption and is effective for annual and interim periods beginning after December 15, 2017. We are currently evaluating the impact that this standard will have on our consolidated financial statements. In June 2014, the FASB issued ASU No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved After a Requisite Service Period” (“ASU 2014-12”). Companies commonly issue share-based payment awards that require a specific performance target to be achieved in order for employees to become eligible to vest in the awards. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. The performance target should not be reflected in estimating the grant date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. ASU 2014-12 will be effective for the Company’s fiscal year beginning fiscal 2016 and interim reporting periods within that year, using either the retrospective or prospective transition method. Early adoption is permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”), to provide guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company’s fiscal year beginning January 1, 2016 and subsequent interim periods, with earlier adoption permitted. We will adopt this guidance in the first quarter of 2016. We do not expect the adoption of this guidance to have a material effect on our consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory” (“ASU 2015-11”). ASU 2015-11 requires that an entity should measure inventory within the scope of this pronouncement at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The pronouncement does not apply to inventory that is being measured using the last-in, first-out (“LIFO”) or the retail inventory method. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. ASU 2015-11 will be effective for the Company’s fiscal year beginning January 1, 2017 and subsequent interim periods, with earlier adoption permitted. We are currently evaluating the effect of the adoption of this guidance on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes” ("ASU 2015-17'), which amends existing guidance to require that deferred income tax liabilities and assets be classified as noncurrent in a classified balance sheet, and eliminates the prior guidance which required an entity to separate deferred tax liabilities and assets into a current amount and a noncurrent amount in a classified balance sheet. The standard is effective for the Company’s fiscal year 2017. Early adoption is permitted. As permitted by ASU 2015-17, the Company early-adopted this standard and applied it retrospectively to all periods of the tax provision presented. As the Company has a full valuation allowance against the deferred assets, there is no impact to the consolidated financial statements. The Company has reflected the change of this pronouncement in Note 12 to the consolidated financial statements.

Note 2 - Summary of Significa21

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2015 2014 Stock options to purchase common stock 8,177,291 2,291,783 Warrants to purchase common stock 3,066,447 1,793,887 Rights to common stock - 566,038

Note 4 - Property and Equipme22

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2015 2014 Medical equipment 5 $ 454 $ 367 Computer equipment 3 56 39 Furniture and fixtures 7 24 13 534 419 Less: Accumulated depreciation and amortization (295 ) (232 ) Property and equipment, net $ 239 $ 187

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2015 December 31, 2014 Accrued professional fees $ 388 $ 117 Accrued clinical trial costs 112 - Accrued bonuses 613 - Accrued vacation 68 86 Other accruals 112 20 Total accrued liabilities $ 1,293 $ 223

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2016 $ 1,894 2017 2,124 2018 1,161 2019 34 Total payments 5,213 Less: Amount representing interest (380 ) Present value of obligations 4,833 Less: Notes payable, current portion 4,833 Note payable, noncurrent portion $ -

Note 7 - Commitments and Cont25

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2016 229 2017 58 Total minimum lease payments $ 287

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 0.53 934,313 September 2014 Common Shares September 30, 2024 $ 0.53 471,698 October 2014 Common Shares October 13, 2019 $ 0.53 237,000 October 2014 Common Shares October 31, 2019 $ 0.53 3,750 November 2014 Common Shares November 12, 2019 $ 0.53 100,000 February 2015 Common Shares February 17, 2025 $ 0.50 605,556 March 2015 Common Shares March 26, 2025 $ 0.34 11,628 May 2015 Common Shares May 12, 2025 $ 0.53 289,827 May 2015 Common Shares May 14, 2025 $ 0.37 25,000 May 2015 Common Shares May 17, 2020 $ 0.53 172,675 December 2015 Common Shares December 16, 2025 $ 0.70 215,000 3,066,447

Note 9 - Summary of Stock Opt27

Note 9 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Year Ended December 31, 2015 Year Ended December 31, 2014 Weighted Weighted Weighted Average Aggregate Weighted Average Aggregate Number Average Remaining Intrinsic Number Average Remaining Intrinsic of Exercise Contractual Value of Exercise Contractual Value Shares Price Term (years) (in thousands) Shares Price Term (years) (in thousands) Options outstanding, beginning of period 2,291,783 $ 1.02 9.32 $ - 363,413 $ 1.24 8.80 Options granted 6,031,004 $ 0.73 1,901,476 $ 0.60 Options assumed from PLC - $ - 68,238 $ 10.24 Options exercised - $ - (160 ) $ 0.12 Options canceled (145,496 ) $ 0.69 (41,184 ) $ 1.83 Options outstanding, end of period 8,177,291 $ 0.81 9.37 $ 1,194,180 2,291,783 $ 1.02 9.32 $ - Vested and exercisable and expected to vest, end of period 7,418,006 $ 0.82 9.33 $ 1,094,069 2,099,687 $ 1.06 9.29 $ - Vested and exercisable, end of period 974,849 $ 1.58 7.20 $ 143,458 519,901 $ 2.45 7.89 $ -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2015 Price Term (Years) December 31, 2015 Price $0.33 100,000 $ 0.33 9.37 - $ - $0.46 - $0.47 635,000 $ 0.47 9.11 - $ - $0.60 1,768,980 $ 0.60 8.55 585,542 $ 0.60 $0.75 4,949,004 $ 0.75 9.97 - $ - $0.89 - $0.99 335,000 $ 0.96 9.60 - $ - $1.24 312,373 $ 1.24 6.79 312,373 $ 1.24 $7.00 - $9.00 57,603 $ 8.64 1.61 57,603 $ 8.64 $12.00 - $18.63 19,081 $ 15.29 1.75 19,081 $ 15.29 $37.00 250 $ 37.00 1.73 250 $ 37.00 8,177,291 $ 0.81 9.37 974,849 $ 1.58
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2015 2014 Expected term (in years) 5% 5% Average volatility 63% 61% Risk-free interest rate 1.70% 1.80% Dividend yield 0% 0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2015 2014 Research and development $ 18 $ 5 Selling, general and administrative 202 179 Total $ 220 $ 184

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2015 2014 Income tax provision (benefit) at statutory rate (34 )% (34 )% State income taxes, net of federal benefit (6 )% (6 )% Merger transaction costs 0 % 6 % Change in valuation allowance 39 % 37 % Other 1 % (3 )% Effective tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 10,726 $ 5,770 Capitalized start up costs 7,225 7,751 Research and development credits 248 189 Accruals and reserves 497 169 Total deferred tax assets 18,696 13,879 Deferred tax liabilities: Fixed assets and depreciation (8 ) (13 ) Valuation allowance (18,688 ) (13,866 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2015 2014 Balance at the beginning of the year $ 97 $ 83 Additions based upon tax positions related to the current year 31 14 Balance at the end of the year $ 128 $ 97

Note 12 - Segments and Geogra29

Note 12 - Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2015 2014 Asia $ 889 $ 83 Europe and Middle East 551 - Rest of the world 7 7 Total $ 1,447 $ 90
Long-lived Assets by Geographic Areas [Table Text Block]	Year Ended December 31, 2015 2014 United States $ 100 $ 60 Europe 99 106 Asia 32 - Canada 8 21 Total $ 239 $ 187

Note 1 - The Company and Basi30

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Nov. 24, 2015	May. 14, 2015	Sep. 23, 2014	Dec. 31, 2015	Dec. 31, 2014	Feb. 28, 2015	Nov. 30, 2014
Convertible Debt [Member] | Accrued Interest [Member]
Extinguishment of Debt, Amount			$ 522,000
Convertible Debt [Member]
Extinguishment of Debt, Amount			$ 4,875,000
Viveve [Member]
Conversion of Stock, Shares Issued			3,743,282
Percentage of Total Common Stock Attributable to Viveve Capital Stock Converted			62.00%
Payment to Each NonAccredited Investors for Converted Shares Upon Merger			$ 16,000
GBS [Member]
Stock Issued During Period, Shares, Other			943,596
Private Placement [Member]
Stock Issued During Period, Shares, New Issues	8,573,385	32,432,432
Warrant Term				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				940,189
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.53
Share Price	$ 0.70	$ 0.37
Proceeds from Issuance Of Private Placement Gross	$ 6,000,000	$ 12,000,000
Proceeds from Issuance of Private Placement Net	5,393,000	11,040,000
Extinguishment of Debt, Amount					$ 5,397,000
Extinguishment of Warrant Liabilities			$ 572,000		572,000
Proceeds from Issuance of Private Placement			6,000,000		4,204,000
Debt Conversion, Original Debt, Amount			$ 1,500,000		1,546,000
Stock Issued During Period, Shares, New Issues			11,305,567
Stock Issued During Period, Shares, Conversion of Convertible Securities			101,365
Warrant Term			5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			940,189	3,066,447		605,556	382,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.53			$ 0.50	$ 0.53
Proceeds from Issuance Of Private Placement Gross	6,000,000	12,000,000
Proceeds from Issuance of Private Placement Net	$ 5,393,000	$ 11,040,000
Retained Earnings (Accumulated Deficit)				$ (48,511,000)	$ (36,085,000)

Note 2 - Summary of Significa31

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Minimum [Member]
Property, Plant and Equipment Estimated Useful Lives1	3 years
Maximum [Member]
Property, Plant and Equipment Estimated Useful Lives1	7 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Four Customers [Member]
Concentration Risk, Percentage	87.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Concentration Risk Number of Customers		2
Concentration Risk, Percentage		91.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk Number of Customers	4
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage	86.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk Number of Customers	3
Medical Equipment, Sales Demos [Member]
Property, Plant and Equipment Estimated Useful Lives1	5 years
Number of Financial Institutions	1
Allowance for Doubtful Accounts Receivable	$ 0	$ 0
Warranty Period	1 year

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	8,177,291	2,291,783
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	3,066,447	1,793,887
Rights to Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		566,038

Note 4 - Property and Equipme33

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Depreciation	$ 77,000	$ 56,000

Note 4 - Equipment, Furniture,

Note 4 - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Equipment [Member]
Useful life	5 years
Property and equipment, gross	$ 454	$ 367
Computer Equipment [Member]
Useful life	3 years
Property and equipment, gross	$ 56	39
Furniture and Fixtures [Member]
Useful life	7 years
Property and equipment, gross	$ 24	13
Property and equipment, gross	534	419
Less: Accumulated depreciation and amortization	(295)	(232)
Property and equipment, net	$ 239	$ 187

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued professional fees	$ 388	$ 117
Accrued clinical trial costs	112
Accrued bonuses	613
Accrued vacation	68	86
Other accruals	112	20
Total accrued liabilities	$ 1,293	$ 223

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual)	Jul. 15, 2015USD ($)	Apr. 06, 2015USD ($)	Mar. 16, 2015USD ($)	Feb. 19, 2015USD ($)	Oct. 02, 2014USD ($)	May. 31, 2015$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares	Sep. 23, 2014$ / sharesshares	Apr. 06, 2015	Dec. 31, 2015USD ($)shares	Feb. 28, 2015$ / sharesshares	Dec. 31, 2014USD ($)	Nov. 30, 2014$ / sharesshares
September 2014 Term Loan [Member] | Second Tranche [Member]
Proceeds from Loans		$ 500,000	$ 500,000	$ 500,000
Debt Instrument, Face Amount							$ 1,500,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments									30
Debt Instrument, Interest Rate, Stated Percentage		5.00%	5.06%	5.00%					5.00%
September 2014 Term Loan [Member] | First Tranche [Member]
Proceeds from Loans					$ 2,500,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments					30
Debt Instrument, Interest Rate, Stated Percentage					5.25%
September 2014 Term Loan [Member] | Third Tranche [Member]
Proceeds from Loans	$ 1,000,000
Debt Instrument Repayment Of Principal And Interest Number Of Installments	30
Debt Instrument, Interest Rate, Stated Percentage							6.56%
September 2014 Term Loan [Member]
Debt Instrument, Face Amount							$ 5
Notes Payable, Current										$ 4,800,000		$ 2,500,000
Warrant Term						10 years	10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares						25,000	471,698
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 0.37	$ 0.53
Loans Payable [Member]
Repayments of Debt					$ 1,631,000
Notes Payable, Current										$ 4,833,000		$ 2,500,000
Warrant Term								5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares								940,189		3,066,447	605,556		382,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 0.53			$ 0.50		$ 0.53

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 1,894
2,017	2,124
2,018	1,161
2,019	34
Total payments	5,213
Less: Amount representing interest	(380)
Present value of obligations	4,833
Notes Payable, Current	$ 4,833

Note 7 - Commitments and Cont38

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Leases, Rent Expense	$ 210,000	$ 171,000

Note 7 - Commitments and Cont39

Note 7 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2015USD ($)
2,016	$ 229
2,017	58
Total minimum lease payments	$ 287

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual) - USD ($)	Nov. 24, 2015	May. 14, 2015	Jun. 30, 2015	May. 31, 2015	Mar. 31, 2015	Feb. 28, 2015	Sep. 30, 2014	Sep. 23, 2014	Nov. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Private Placement [Member]
Right to Shares Agreement Additional Shares Issuable										0
Right to Shares Agreement Common Shares Cancelled											854,989
Right to Shares Agreement Obligated to Issue Shares											956,354
Right to Shares Agreement Not Issued Due to Beneficial Ownership Limitations Shares											101,365
Right to Shares Agreement Delivery of Shares Days Obligated											3 days
Right To Shares Agreement Common Stock Shares Issued			566,038								390,316
Stock Issued During Period, Shares, New Issues	8,573,385	32,432,432
Share Price	$ 0.70	$ 0.37
Proceeds from Issuance Of Private Placement Gross	$ 6,000,000	$ 12,000,000
Proceeds from Issuance of Private Placement Net	5,393,000	11,040,000
Class of Warrant or Right, Outstanding										3,066,447
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										940,189
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.53
Warrant Term										5 years
September 2014 Term Loan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							471,698
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.53
Warrant Term							10 years
Warrants and Rights Outstanding							$ 622,000
Fair Value Assumptions, Expected Dividend Rate							0.00%
Fair Value Assumptions, Expected Volatility Rate							77.00%
Fair Value Assumptions, Risk Free Interest Rate							2.50%
Amortization of Debt Discount (Premium)										$ 187,000	$ 48,000
Unamortized Debt Issuance Expense										387,000
Warrant [Member] | Minimum [Member]
Fair Value Assumptions, Risk Free Interest Rate									1.55%
Warrant [Member] | Maximum [Member]
Fair Value Assumptions, Risk Free Interest Rate									1.65%
Warrant [Member] | Vendors And Nonemployee [Member]
Allocated Share-based Compensation Expense										40,000	137,000
Warrant [Member] | Employees [Member]
Allocated Share-based Compensation Expense										$ 244,000
Warrant [Member] | September 2014 Term Loan [Member]
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				80.10%
Fair Value Assumptions, Risk Free Interest Rate				2.23%
Fair Value Assumptions, Expected Term				10 years
Warrant [Member]
Fair Value Assumptions, Expected Dividend Rate						0.00%			0.00%
Fair Value Assumptions, Expected Volatility Rate						77.60%			61.30%
Fair Value Assumptions, Risk Free Interest Rate						2.14%
Fair Value Assumptions, Expected Term						10 years			5 years
Vendors And Nonemployee [Member]
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period										41,250
March 2015 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					11,628
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.34
Fair Value Assumptions, Expected Dividend Rate					0.00%
Fair Value Assumptions, Expected Volatility Rate					78.90%
Fair Value Assumptions, Risk Free Interest Rate					1.94%
Fair Value Assumptions, Expected Term					10 years
Allocated Share-based Compensation Expense										$ 3,000
May 2015 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				289,827
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.53
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				80.10%
Fair Value Assumptions, Risk Free Interest Rate				2.28%
Fair Value Assumptions, Expected Term				10 years
Allocated Share-based Compensation Expense										73,000
May 2015 Issuance Second Contractor [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				172,675
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.53
Fair Value Assumptions, Expected Dividend Rate				0.00%
Fair Value Assumptions, Expected Volatility Rate				64.40%
Fair Value Assumptions, Risk Free Interest Rate				1.54%
Fair Value Assumptions, Expected Term				5 years
Allocated Share-based Compensation Expense										$ 47,000
December 2015 Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										215,000
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.70
Warrant Term										10 years
Fair Value Assumptions, Expected Dividend Rate										0.00%
Fair Value Assumptions, Expected Volatility Rate										76.80%
Fair Value Assumptions, Risk Free Interest Rate										2.27%
Allocated Share-based Compensation Expense										$ 130,000
September 2014 Term Loan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				25,000			471,698
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.37			$ 0.53
Warrant Term				10 years			10 years
Warrants and Rights Outstanding				$ 10,000
Amortization of Debt Discount (Premium)										10,000
Unamortized Debt Issuance Expense										$ 0
Stock Issued During Period, Shares, New Issues								11,305,567
Proceeds from Issuance Of Private Placement Gross	6,000,000	12,000,000
Proceeds from Issuance of Private Placement Net	$ 5,393,000	$ 11,040,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						605,556		940,189	382,000	3,066,447
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.50		$ 0.53	$ 0.53
Warrant Term								5 years
Percent Of Outstanding Loan Amount										1.00%
Allocated Share-based Compensation Expense										$ 220,000	$ 184,000

Note 8 - Common Stock - Summary

Note 8 - Common Stock - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Range One [Member]
Expiration Date	Sep. 23, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	934,313
Range Two [Member]
Expiration Date	Sep. 30, 2024
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	471,698
Range Three [Member]
Expiration Date	Oct. 13, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	237,000
Range Four [Member]
Expiration Date	Oct. 31, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	3,750
Range Five [Member]
Expiration Date	Nov. 12, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	100,000
Range Six [Member]
Expiration Date	Feb. 17, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.50
Shares Outstanding Under Warrants (in shares)	605,556
Range Seven [Member]
Expiration Date	Mar. 26, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.34
Shares Outstanding Under Warrants (in shares)	11,628
Range Eight [Member]
Expiration Date	May 12, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	289,827
Range Nine [Member]
Expiration Date	May 14, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.37
Shares Outstanding Under Warrants (in shares)	25,000
Range Ten [Member]
Expiration Date	May 17, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.53
Shares Outstanding Under Warrants (in shares)	172,675
Range Eleven [Member]
Expiration Date	Dec. 16, 2025
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.70
Shares Outstanding Under Warrants (in shares)	215,000
Shares Outstanding Under Warrants (in shares)	3,066,447

Note 9 - Summary of Stock Opt42

Note 9 - Summary of Stock Options (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jul. 22, 2015	Jul. 21, 2015
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	322,069
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 233 days
Conversion of Stock Exchange Ratio	0.0080497
Two Thousand Five Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	22,095
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	22,095
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 12.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 131 days
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	5 years
The 2013 Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,944,644
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	7,833,127
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.74
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 186 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				10,100,000	3,111,587
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.39	$ 0.32
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Allocated Share-based Compensation Expense	$ 220,000	$ 184,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 2,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 259 days
Acceleration of Vesting of Approximately 140,000 Affected Stock Options [Member] | Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense		$ 103,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	8,177,291	2,291,783	363,413
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.81	$ 1.02	$ 1.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 135 days	9 years 116 days	8 years 292 days
Allocated Share-based Compensation Expense	$ 220,000	$ 184,000
Stock Options Acceleration of Vesting Number		140,000

Note 9 - Summary of Stock Opt43

Note 9 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Options outstanding, beginning of period (in shares)	2,291,783	363,413
Options outstanding, beginning of period (in dollars per share)	$ 1.02	$ 1.24
Options outstanding, beginning of period	9 years 135 days	9 years 116 days
Options granted (in shares)	6,031,004	1,901,476
Options granted (in dollars per share)	$ 0.73	$ 0.60
Options assumed from PLC (in shares)		68,238
Options assumed from PLC (in dollars per share)		$ 10.24
Options exercised (in shares)		(160)
Options exercised (in dollars per share)		$ 0.12
Options canceled (in shares)	(145,496)	(41,184)
Options canceled (in dollars per share)	$ 0.69	$ 1.83
Options outstanding, end of period (in shares)	8,177,291	2,291,783
Options outstanding, end of period (in dollars per share)	$ 0.81	$ 1.02
Options outstanding, end of period	$ 1,194,180
Vested and exercisable and expected to vest, end of period (in shares)	7,418,006	2,099,687
Vested and exercisable and expected to vest, end of period (in dollars per share)	$ 0.82	$ 1.06
Vested and exercisable and expected to vest, end of period	9 years 120 days	9 years 105 days
Vested and exercisable and expected to vest, end of period	$ 1,094,069
Vested and exercisable, end of period (in shares)	974,849	519,901
Vested and exercisable, end of period (in dollars per share)	$ 1.58	$ 2.45
Vested and exercisable, end of period	7 years 73 days	7 years 324 days
Vested and exercisable, end of period	$ 143,458

Note 9 - Summary of Stock Opt44

Note 9 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Range One [Member]
Range of Exercise Prices (in dollars per share)	$ 0.33
Options Outstanding, Number (in shares) | shares	100,000
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 0.33
Options Outstanding - Weighted Average Remaining Contractual Term	9 years 135 days
Options Exercisable - Number (in shares) | shares
Options Exercisable - Weighted Average Exercise Price (in dollars per share)
Range Two [Member]
Range of Exercise Prices (in dollars per share)	$ 0.47
Options Outstanding, Number (in shares) | shares	635,000
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 0.47
Options Outstanding - Weighted Average Remaining Contractual Term	9 years 40 days
Options Exercisable - Number (in shares) | shares
Options Exercisable - Weighted Average Exercise Price (in dollars per share)
Range of Exercise Prices, Lower Range (in dollars per share)	$ 0.46
Range of Exercise Prices, Upper Range (in dollars per share)	0.47
Range Three [Member]
Range of Exercise Prices (in dollars per share)	$ 0.60
Options Outstanding, Number (in shares) | shares	1,768,980
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 0.60
Options Outstanding - Weighted Average Remaining Contractual Term	8 years 200 days
Options Exercisable - Number (in shares) | shares	585,542
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 0.60
Range Four [Member]
Range of Exercise Prices (in dollars per share)	$ 0.75
Options Outstanding, Number (in shares) | shares	4,949,004
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 0.75
Options Outstanding - Weighted Average Remaining Contractual Term	9 years 354 days
Options Exercisable - Number (in shares) | shares
Options Exercisable - Weighted Average Exercise Price (in dollars per share)
Range Five [Member]
Range of Exercise Prices (in dollars per share)	$ 0.96
Options Outstanding, Number (in shares) | shares	335,000
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 0.96
Options Outstanding - Weighted Average Remaining Contractual Term	9 years 219 days
Options Exercisable - Number (in shares) | shares
Options Exercisable - Weighted Average Exercise Price (in dollars per share)
Range of Exercise Prices, Lower Range (in dollars per share)	$ 0.89
Range of Exercise Prices, Upper Range (in dollars per share)	0.99
Range Six [Member]
Range of Exercise Prices (in dollars per share)	$ 1.24
Options Outstanding, Number (in shares) | shares	312,373
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 1.24
Options Outstanding - Weighted Average Remaining Contractual Term	6 years 288 days
Options Exercisable - Number (in shares) | shares	312,373
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 1.24
Range Seven [Member]
Range of Exercise Prices (in dollars per share)	$ 8.64
Options Outstanding, Number (in shares) | shares	57,603
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 8.64
Options Outstanding - Weighted Average Remaining Contractual Term	1 year 222 days
Options Exercisable - Number (in shares) | shares	57,603
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 8.64
Range of Exercise Prices, Lower Range (in dollars per share)	7
Range of Exercise Prices, Upper Range (in dollars per share)	9
Range Eight [Member]
Range of Exercise Prices (in dollars per share)	$ 15.29
Options Outstanding, Number (in shares) | shares	19,081
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 15.29
Options Outstanding - Weighted Average Remaining Contractual Term	1 year 273 days
Options Exercisable - Number (in shares) | shares	19,081
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 15.29
Range of Exercise Prices, Lower Range (in dollars per share)	12
Range of Exercise Prices, Upper Range (in dollars per share)	18.63
Range Nine [Member]
Range of Exercise Prices (in dollars per share)	$ 37
Options Outstanding, Number (in shares) | shares	250
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 37
Options Outstanding - Weighted Average Remaining Contractual Term	1 year 266 days
Options Exercisable - Number (in shares) | shares	250
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 37
Range of Exercise Prices (in dollars per share)	$ 0.81
Options Outstanding, Number (in shares) | shares	8,177,291
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 0.81
Options Outstanding - Weighted Average Remaining Contractual Term	9 years 135 days
Options Exercisable - Number (in shares) | shares	974,849
Options Exercisable - Weighted Average Exercise Price (in dollars per share)	$ 1.58

Note 9 - Summary of Stock Opt45

Note 9 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Expected term (in years)	5 years	5 years
Average volatility	63.00%	61.00%
Risk-free interest rate	1.70%	1.80%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%

Note 9 - Summary of Stock Opt46

Note 9 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	$ 18	$ 5
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	202	179
Allocated Share-based Compensation Expense	$ 220	$ 184

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 26,927,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	214,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards		$ 26,915,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	212,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	4,822,000	2,257,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	248,000	189,000
Unrecognized Tax Benefits	$ 128,000	$ 97,000	$ 83,000

Note 10 - Provision for Income

Note 10 - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income tax provision (benefit) at statutory rate	(34.00%)	(34.00%)
State income taxes, net of federal benefit	(6.00%)	(6.00%)
Merger transaction costs	0.00%	6.00%
Change in valuation allowance	39.00%	37.00%
Other	1.00%	(3.00%)
Effective tax rate	0.00%	0.00%

Note 10 - Significant Component

Note 10 - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 10,726	$ 5,770
Capitalized start up costs	7,225	7,751
Deferred Tax Assets, Tax Credit Carryforwards, Research	248	189
Accruals and reserves	497	169
Total deferred tax assets	18,696	13,879
Deferred tax liabilities:
Fixed assets and depreciation	(8)	(13)
Valuation allowance	$ (18,688)	$ (13,866)

Note 10 - Unrecognized Tax Bene

Note 10 - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Balance	$ 97,000	$ 83,000
Additions based upon tax positions related to the current year	31,000	14,000
Balance	$ 128,000	$ 97,000

Note 11 - Related Party Trans51

Note 11 - Related Party Transactions (Details Textual)	Oct. 04, 2007shares	Sep. 23, 2014shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)
Stellartech Research Corporation [Member] | Based On Postmerger Exchange Ratio [Member]
Stock Issued During Period, Shares, New Issues	2,415
Stellartech Research Corporation [Member]
Shares of Common Stock Subject to Repurchase			0
Stock Issued During Period, Shares, New Issues	300,000
Conversion of Stock Exchange Ratio	0.0080497
Right to Repurchase Stock Term			4 years
Related Party Transaction, Amounts of Transaction | $			$ 3,446,000	$ 484,000
Stock Issued During Period, Shares, New Issues		11,305,567

Note 12 - Revenue from Unaffili

Note 12 - Revenue from Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Asia [Member]
Revenues	$ 889	$ 83
Europe And Middle East [Member]
Revenues	551
Rest Of The World [Member]
Revenues	7	$ 7
Revenues	$ 1,447	$ 90

Note 12 - Long-lived Assets by

Note 12 - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
UNITED STATES
Property and equipment, net	$ 100	$ 60
Europe [Member]
Property and equipment, net	99	$ 106
Asia [Member]
Property and equipment, net	32
CANADA
Property and equipment, net	8	$ 21
Property and equipment, net	$ 239	$ 187

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member]	Mar. 18, 2016USD ($)	Jan. 31, 2016
September 2014 Term Loan [Member]
Minimum Required Cash Balance	$ 3,000,000
Commercial Relationship, Contractual Term	3 years
Number Of Viveve Systems Units, To Be Purchased In Next Twelve Months		47
Number Of Viveve Systems Units, To Be Purchased In Year Two		75
Number Of Viveve Systems Units, To Be Purchased In Year Three		109